DJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma: A possible role in carcinogenesis
Authors:
- Wesam M. OsmanWOWesam M. Osman
- Rasha M. Abd El AttiRARasha M. Abd El Atti
- Hoda H. Abou GabalHGHoda H. Abou Gabal
Open Access
- 1 December 2013
- journal article
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 25 (4) , 223-230
Abstract
Androgen plays a fundamental role in the growth and differentiation of prostate. Androgen receptor (AR) expression may represent a potential marker of prognosis in prostate cancer. However, there have been variable results regarding its ability to predict clinical progression. Despite the oncogenic properties of DJ-1, its significance in prostate cancer development and progression is not well understood. This research shed some light on the possible role of immunohistochemical expression of DJ-1 in clinically localized prostatic carcinoma in relation to the established role of AR and other clinicopathologic parameters. The immunohistochemical expression of AR and DJ-1 was evaluated in 129 samples including benign hyperplasia (n = 60) and prostatic carcinoma (n = 69). The mean value of AR immunostaining was significantly higher in prostatic carcinomas than in benign hyperplasia (P = 0.001). A significant inverse correlation was found between AR immunostaining and the grade of prostatic carcinomas. A significantly higher median DJ-1 score was found in prostatic carcinoma than in benign hyperplasia (P = 0.0001). There was a significant direct correlation between AR and DJ-1 score (P = 0.0001). AR is more sensitive in predicting prostatic carcinoma than DJ-1 but DJ-1 is more specific than AR. AR nuclear expression was consistently present in benign and adenocarcinoma epithelium. But, there may be limited clinical use for AR expression in localized carcinoma due to its constant heterogeneity. DJ-1 with its oncogenic properties, specificity for prostatic carcinoma and homogenous expression gives an ideal complementary role to AR in the detection and treatment of prostatic carcinomas.Keywords
This publication has 34 references indexed in Scilit:
- Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature reviewAsian Journal of Andrology, 2008
- Ectopic expression of neurotrophic peptide derived from saposin C increases proliferation and upregulates androgen receptor expression and transcriptional activity in human prostate cancer cellsAsian Journal of Andrology, 2007
- Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cellsAsian Journal of Andrology, 2007
- Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: Prognostic implicationsUrology, 2005
- Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese populationUrology, 2005
- High Level of Androgen Receptor Is Associated With Aggressive Clinicopathologic Features and Decreased Biochemical Recurrence-free Survival in ProstateAmerican Journal of Surgical Pathology, 2004
- Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancerPathology International, 2001
- ANDROGEN RECEPTOR EXPRESSION IN PROSTATE CANCER LYMPH NODE METASTASES IS PREDICTIVE OF OUTCOME AFTER SURGERYJournal of Urology, 1999
- THE PROGNOSTIC VALUE OF PRETREATMENT EXPRESSION OF ANDROGEN RECEPTOR AND BCL-2 IN HORMONALLY TREATED PROSTATE CANCER PATIENTSJournal of Urology, 1997
- Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinomaCancer, 1996